The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?

Journal of Hepatology, Journal Year: 2021, Volume and Issue: 76(4), P. 771 - 780

Published: Dec. 9, 2021

Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent, yet largely underappreciated condition which closely associated with obesity and metabolic disease. Despite affecting an estimated 1 in 4 adults globally, NAFLD absent on national global health agendas.We collected data from 102 countries, accounting for 86% of the world population, policies, guidelines, civil society engagement, clinical management, epidemiologic data. A preparedness index was developed by coding questions into 6 domains (policies, awareness, epidemiology data, detection, care management) categorising responses as high, medium, low; multiple correspondence analysis then applied.The highest scoring countries were India (42.7) United Kingdom (40.0), 32 (31%) zero out 100. For 5 minority categorised high-level while majority low-level. No country had or sub-national strategy <2% different strategies related conditions included any mention NAFLD. National guidelines present only countries.Although pressing public problem, no found to be well prepared address it. There need at levels.Around third scored policy index, over 50/100. Although comprehensive response lacking all countries. Policies levels are urgently needed.

Language: Английский

---

The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

The Lancet, Journal Year: 2021, Volume and Issue: 399(10319), P. 61 - 116

Published: Dec. 2, 2021

Language: Английский

---

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease

Hepatology International, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Language: Английский

---

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

Clinical and Molecular Hepatology, Journal Year: 2021, Volume and Issue: 28(2), P. 150 - 163

Published: Nov. 10, 2021

Fatty liver is now a major cause of disease in the Asia-Pacific region. Liver diseases this region have distinctive characteristics. First, fatty frequently observed lean/normal-weight individuals. However, there no standard definition unique phenotype. Second, often patients with concomitant viral hepatitis. The exclusion hepatitis from non-alcoholic limits its value and detracts investigation holistic management coexisting Third, liver-associated hepatocellular carcinoma (HCC) generally categorized as non-B non-C HCC. Fourth, population aging rapidly, it imperative to develop practicable, low-intensity exercise program for elderly patients. Fifth, most nonspecialized healthcare professionals still lack an awareness significance both terms intrahepatic extrahepatic cancer. Recently, international expert panel proposed new liver: metabolic dysfunction-associated (MAFLD). One feature MAFLD that dysfunction prerequisite diagnosis. Pertinent regional issues, also provides diagnostic criteria Furthermore, independent any disease, including Therefore, may be more suitable In review, we introduce characteristics discuss advantages improving clinical practice

Language: Английский

---

Metabolic dysfunction-associated fatty liver disease: a year in review

Current Opinion in Gastroenterology, Journal Year: 2022, Volume and Issue: 38(3), P. 251 - 260

Published: Feb. 9, 2022

Purpose of review In 2020, a novel comprehensive redefinition fatty liver disease was proposed by an international panel experts. This aims to explore current evidence regarding the impact this new definition on understanding epidemiology, pathogenesis, diagnosis, and clinical trials for disease. Recent findings The effectiveness metabolic dysfunction-associated (MAFLD) compared existing criteria nonalcoholic (NAFLD). data robustly suggest superior utility MAFLD in identifying patients at high risk dysfunction, hepatic extra-hepatic complications, as well those who would benefit from genetic testing, including with concomitant diseases. change name also appears have improved awareness among physicians. Summary transformation NAFLD represents important milestone, which indicates significant tangible progress towards more inclusive, equitable, patient-centred approach addressing profound challenges Growing has illustrated broader specific contexts that tremendous potential positively influencing diagnosis treatment. addition, momentum accompanying included widespread public attention unique burden previously underappreciated

Language: Английский

---

MAFLD: an optimal framework for understanding liver cancer phenotypes

Journal of Gastroenterology, Journal Year: 2023, Volume and Issue: 58(10), P. 947 - 964

Published: July 20, 2023

Hepatocellular carcinoma has a substantial global mortality burden which is rising despite advancements in tackling the traditional viral risk factors. Metabolic (dysfunction) associated fatty liver disease (MAFLD) most prevalent disease, increasing parallel with epidemics of obesity, diabetes and systemic metabolic dysregulation. MAFLD major factor behind this sustained rise HCC incidence, both as single entity often via synergistic interactions other diseases. Mechanisms MAFLD-related are complex but crucially underpinned by dysregulation variable contributions from interacting modifiers related to environment, genetics, dysbiosis immune distinct clinical presentation, notably its common occurrence non-cirrhotic disease. This just one several challenges effective surveillance programmes. The response immune-checkpoint therapy currently controversial, further complicated high prevalence individuals aetiologies. In review, we highlight current data on epidemiology, characteristics, outcomes screening controversies. addition, concepts that have arisen because paradigm such MAFLD/NAFLD non-overlapping groups, dual aetiology tumours sub-phenotypes reviewed.

Language: Английский

---

Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC

Clinical Gastroenterology and Hepatology, Journal Year: 2024, Volume and Issue: 22(6), P. 1275 - 1285.e2

Published: Feb. 15, 2024

Language: Английский

---

Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 23, 2025

With the advent of direct-acting antiviral agents for hepatitis C (HCV) in 2013 and increased uptake vaccines B, burden viral-related chronic liver disease has significantly decreased [1, 2]. It was predicted that this would lead to a plateau or even decrease incidence primary cancer (PLC) especially younger cohorts specific ethnic groups [3-5]. However, concurrent rise metabolic syndrome alcohol use disorder led emergence steatotic as most common cause [6-8]. previously unknown how shift aetiology affected recent trends PLC incidence, prevalence mortality. Utilising Global Burden Disease (GBD) Study 2021, Danpanichkul et al. demonstrated cases deaths United States have steadily from 2000 mostly due alcohol-associated (ALD) dysfunction associated (MASLD) [9]. They found ALD be fastest growing PLC, which contrasts prior data GBD 2019, identified MASLD PLC. The authors astutely point out harmful context COVID-19 pandemic cardio States, are likely driving rapid both MASLD. Despite this, HCV is still leading contributed highest prevalence, by albeit with slower growth recently evaluated era 2015 2021. paper aligns studies shown an frequency males older adults, but constraints data, unable evaluate race/ethnicity distinguish between type i.e., hepatocellular carcinoma cholangiocarcinoma [3, 10]. work highlights importance continuing bolster screening treatment programs not only reduce also prevent morbidity mortality we yet seen peak HCV-related projected third 2040, further study will required address many unanswered questions including ALD, MetALD, best refine identify patients without cirrhosis, particularly large non-cirrhotic population. Still, important advances our knowledge evolving etiologic drivers their impact on cancer-related death disability-adjusted life years. Public health policies focused curbing SLD, like efforts made eradicate HCV, meaningfully ongoing Kelly Torosian: writing – original draft, conceptualization. Veeral Ajmera: conceptualization, review editing, draft. declare no conflicts interest. This article linked al papers. To view these articles, visit https://doi.org/10.1111/apt.18473 https://doi.org/10.1111/apt.18511. Data sharing applicable datasets were generated analysed during current study.

Language: Английский

---

The Egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

Saudi Journal of Gastroenterology, Journal Year: 2022, Volume and Issue: 28(1), P. 3 - 20

Published: Jan. 1, 2022

The landscape of chronic liver disease in Egypt has drastically changed over the past few decades. prevalence metabolic-associated fatty (MAFLD) risen to alarming levels. Despite magnitude problem, no regional guidelines have been developed tackle this disease. This document provides clinical practice key Egyptian opinion leaders on MAFLD screening, diagnosis, and management, covers various aspects management MAFLD. considers our local situations burden for healthcare sector is proposed daily practical use. Particular reference special groups was done whenever necessary.

Language: Английский

---

Food inequity and insecurity and MASLD: burden, challenges, and interventions

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2024, Volume and Issue: 21(10), P. 668 - 686

Published: July 29, 2024

Language: Английский

---